Better diabetes outcomes seen with intranasal GLP-1

04/6/2014 | Medscape (free registration)

Intranasal administration of glucagonlike peptide-1 before meals may help improve postprandial glycemic control without adverse events in patients with poorly controlled type 2 diabetes, according to a small study in Diabetes Care. Data showed those who received intranasal GLP-1 had lower postmeal rises in plasma glucose and plasma glucagon levels, lower glycoalbumin levels and higher 1,5 anhydroglucitol levels compared with the control arm.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA